From the perspective of the Chinese healthcare system, atezolizumab emerges as a cost-effective choice for the first-line treatment of NSCLC patients ineligible for platinum-based chemotherapy.
Keyphrases
- end stage renal disease
- small cell lung cancer
- ejection fraction
- locally advanced
- chronic kidney disease
- newly diagnosed
- single cell
- prognostic factors
- peritoneal dialysis
- cell therapy
- stem cells
- squamous cell carcinoma
- advanced non small cell lung cancer
- rectal cancer
- decision making
- mesenchymal stem cells
- bone marrow
- patient reported
- tyrosine kinase